See more : Highcroft Investments Plc (HCFT.L) Income Statement Analysis – Financial Results
Complete financial analysis of ProSomnus, Inc. (OSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProSomnus, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Richmond Mutual Bancorporation, Inc. (RMBI) Income Statement Analysis – Financial Results
- Enbridge Inc. CUM RED PREF Series B (EBRGF) Income Statement Analysis – Financial Results
- ShinWon Corporation (009275.KS) Income Statement Analysis – Financial Results
- PennantPark Investment Corporation (PNNT) Income Statement Analysis – Financial Results
- Zhuhai Bojay Electronics Co.,Ltd. (002975.SZ) Income Statement Analysis – Financial Results
ProSomnus, Inc. (OSA)
About ProSomnus, Inc.
ProSomnus, Inc. manufactures precision oral appliance therapy devices for the treatment of obstructive sleep apnea (OSA). The company was founded in 2016 and is based in Pleasanton, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 27.65M | 19.39M | 14.07M | 8.29M |
| Cost of Revenue | 13.64M | 9.13M | 6.76M | 4.17M |
| Gross Profit | 14.01M | 10.27M | 7.31M | 4.12M |
| Gross Profit Ratio | 50.67% | 52.94% | 51.94% | 49.73% |
| Research & Development | 4.80M | 2.98M | 1.89M | 1.47M |
| General & Administrative | 15.23M | 9.89M | 4.46M | 3.29M |
| Selling & Marketing | 13.09M | 8.87M | 5.78M | 3.52M |
| SG&A | 28.32M | 18.76M | 10.24M | 6.81M |
| Other Expenses | -770.00K | 553.24K | 0.00 | 10.00K |
| Operating Expenses | 33.12M | 21.74M | 12.13M | 8.28M |
| Cost & Expenses | 46.76M | 30.87M | 18.89M | 12.44M |
| Interest Income | 0.00 | 6.12M | 3.25M | 2.01M |
| Interest Expense | 5.38M | 6.12M | 3.25M | 2.01M |
| Depreciation & Amortization | 2.22M | -10.45M | 827.57K | 573.27K |
| EBITDA | -17.74M | -11.48M | -3.99M | -3.57M |
| EBITDA Ratio | -61.06% | -59.17% | -28.33% | -43.14% |
| Operating Income | -19.11M | -1.03M | -4.81M | -4.15M |
| Operating Income Ratio | -69.09% | -5.29% | -34.21% | -50.06% |
| Total Other Income/Expenses | -4.99M | 4.33M | -1.15M | -2.01M |
| Income Before Tax | -24.10M | -7.15M | -5.97M | -6.16M |
| Income Before Tax Ratio | -87.14% | -36.84% | -42.41% | -74.29% |
| Income Tax Expense | 0.00 | -10.45M | 7.65K | 17.67K |
| Net Income | -24.10M | 3.30M | -5.98M | -6.17M |
| Net Income Ratio | -87.14% | 17.04% | -42.47% | -74.50% |
| EPS | -1.49 | 0.33 | -1.51 | -0.38 |
| EPS Diluted | -1.49 | 0.33 | -1.51 | -0.38 |
| Weighted Avg Shares Out | 16.18M | 10.02M | 3.96M | 16.05M |
| Weighted Avg Shares Out (Dil) | 16.18M | 10.02M | 3.96M | 16.05M |
Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
BERN, Switzerland--(BUSINESS WIRE)-- #5G--Adtran today announced that Switzerland's Federal Institute of Metrology METAS has successfully deployed its OSA 3300 HP, improving national timekeeping performance and supporting critical scientific research. As the industry's first high-performance optical cesium atomic clock, the OSA...
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the...
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
HUNTSVILLE, Ala.--(BUSINESS WIRE)-- #5G--Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+)....
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023.
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive...
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the third quarter ended September 30, 2023.
Source: https://incomestatements.info
Category: Stock Reports